Samrat Pharmachem Ltd
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]
- Market Cap ₹ 107 Cr.
- Current Price ₹ 347
- High / Low ₹ 646 / 302
- Stock P/E 15.1
- Book Value ₹ 232
- Dividend Yield 0.29 %
- ROCE 13.6 %
- ROE 10.4 %
- Face Value ₹ 10.0
Pros
- Company's median sales growth is 23.7% of last 10 years
Cons
- Company has a low return on equity of 13.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
65 | 47 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 282 | 286 | |
64 | 46 | 62 | 69 | 87 | 108 | 131 | 170 | 197 | 287 | 279 | 276 | |
Operating Profit | 1 | 1 | 1 | 4 | 6 | 3 | 7 | 9 | 24 | 24 | 2 | 10 |
OPM % | 1% | 2% | 2% | 5% | 6% | 3% | 5% | 5% | 11% | 8% | 1% | 4% |
1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Profit before tax | 0 | 0 | 0 | 3 | 5 | 2 | 6 | 7 | 24 | 23 | 3 | 10 |
Tax % | 41% | 35% | 33% | 37% | 35% | 29% | 27% | 27% | 27% | 26% | 14% | 28% |
0 | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 2 | 7 | |
EPS in Rs | 0.78 | 1.04 | 0.97 | 5.66 | 10.42 | 4.98 | 13.72 | 17.25 | 55.60 | 53.82 | 6.99 | 23.01 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% | 2% | 14% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | 20% |
5 Years: | 16% |
3 Years: | 9% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 36% |
5 Years: | 11% |
3 Years: | -26% |
TTM: | 232% |
Stock Price CAGR | |
---|---|
10 Years: | 30% |
5 Years: | 37% |
3 Years: | -9% |
1 Year: | 3% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 19% |
3 Years: | 14% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 10 | 10 | 11 | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 62 | 69 |
3 | 3 | 6 | 7 | 9 | 7 | 9 | 9 | 8 | 19 | 8 | 10 | |
15 | 10 | 17 | 14 | 13 | 14 | 25 | 19 | 30 | 35 | 48 | 40 | |
Total Liabilities | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 121 |
8 | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 | 10 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 |
24 | 19 | 27 | 29 | 34 | 33 | 50 | 48 | 75 | 104 | 108 | 107 | |
Total Assets | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 121 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | -1 | -0 | -3 | 0 | 2 | -1 | 5 | 17 | -9 | 9 | -10 | |
-0 | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | -3 | -0 | 0 | |
-1 | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | 10 | -11 | 0 | |
Net Cash Flow | 2 | -0 | -0 | -1 | -1 | 1 | -1 | -0 | 14 | -3 | -2 | -10 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 63 | 74 | 93 | 59 | 86 | 69 | 74 | 67 | 72 | 61 | 90 | 72 |
Inventory Days | 45 | 38 | 37 | 41 | 31 | 28 | 55 | 25 | 24 | 43 | 28 | 52 |
Days Payable | 87 | 76 | 104 | 43 | 46 | 45 | 67 | 39 | 45 | 42 | 64 | 53 |
Cash Conversion Cycle | 21 | 36 | 26 | 58 | 70 | 52 | 61 | 53 | 51 | 62 | 53 | 71 |
Working Capital Days | 25 | 39 | 35 | 61 | 65 | 56 | 63 | 54 | 44 | 62 | 58 | 81 |
ROCE % | 7% | 7% | 5% | 16% | 23% | 12% | 22% | 24% | 52% | 35% | 4% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
3 Jun - Crisil upgrades Samrat Pharmachem's bank facilities rating to BBB-/Stable/A3 from BB+/Stable/A4+
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Jun - Copies of Newspaper Publication - Extract of Audited Financial Results FY 24-25 Q4
- Audited Financial Results For The Year Ended March 31, 2025 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today
30 May - Audited FY25 results: Profit ₹988.61L, 10% dividend recommended, 33rd AGM on Sept 25, 2025.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report FY 2024-25 with minor filing delays and fines, no major issues.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
SPL manufactures pharmaceutical ingredient products. It is a major supplier of Iodine Derivatives to the Indian and Foreign Market
and is also present in Salt, Animal Feed, Textile & Tyre Cord manufacturing segment. Company's facilities approved by leading regulatory agencies such as USFDA, GMP, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA